Your session is about to expire
← Back to Search
Deucravacitinib for Lupus
Study Summary
This trial is testing a new drug to see if it is safe and effective for people with lupus.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 220 Patients • NCT04167462Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- There are other requirements or restrictions for participating in the study that are defined in the study's protocol.I have active tuberculosis.
- Group 1: BMS-986165 Dose 1
- Group 2: BMS-986165 Dose 2
- Group 3: BMS-986165 Dose 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do participants aged 55 or older meet the criteria for this medical experiment?
"Patients over 18 years of age and under 75 may submit an application to be a part of this research."
Has a similar study been undertaken in the past?
"To date, 11 clinical trials of BMS-986165 have been run in 401 cities and 36 countries since its inception in 2018. Sponsored by Bristol-Myers Squibb, the initial Phase 2 drug approval study comprised 240 patients with 34 further studies conducted since then."
Is the clinical trial for this new treatment protocol being conducted widely across the US?
"Patients can join this trial at Local Institution - 0131 in New york, Arthritis & Rheumatic Disease Specialties in Aventura, and Local Institution - 0064 in Oklahoma City alongside an additional 41 medical sites."
What is the current participant count for this research endeavor?
"At present, this trial is not accepting new candidates. It was first announced on March 26th 2019 and last updated on October 4th 2022. However, there are currently 122 trials with lupus erythematosus systemic open for recruiting as well 11 studies that require participants to take BMS-986165."
Do I meet the qualifications to partake in this medical experiment?
"This study is seeking 261 participants aged 18–75 with lupus erythematosus, systemic. Additional inclusion criteria include having completed the SLE Study (NCT03252587) and being currently administered a blind trial drug. Exceptions may be granted by the BMS Clinical Trial Physician or designee if unable to receive blinded medication due to extenuating circumstances like delays in approval caused by COVID-19."
Has BMS-986165 been subjected to other experimental trials?
"BMS-986165 saw its initial testing in 2018 at H-T. Centrum Medyczne Spolka z Ograniczona Odpowiedzialnoscia and has since gone on to complete 34 clinical trials. Currently, 11 of these investigations are actively recruiting participants with a majority of them being based out of New york City."
What is the status of regulatory approval for BMS-986165?
"Our team at Power assessed the safety of BMS-986165 as a 2 due to its Phase 2 status, which suggests some clinical evidence for safety but no proof of efficacy."
Are there any vacancies available in this clinical trial?
"Data acquired from clinicaltrials.gov states that this medical research project is no longer recruiting patients, having been initially posted on March 26 2019 and last updated October 4 2022. Nonetheless, there are 133 other trials presently looking for participants."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger